CA2807107C - Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof - Google Patents
Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof Download PDFInfo
- Publication number
- CA2807107C CA2807107C CA2807107A CA2807107A CA2807107C CA 2807107 C CA2807107 C CA 2807107C CA 2807107 A CA2807107 A CA 2807107A CA 2807107 A CA2807107 A CA 2807107A CA 2807107 C CA2807107 C CA 2807107C
- Authority
- CA
- Canada
- Prior art keywords
- hmgb1
- fecal
- invasive method
- protein
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000002550 fecal effect Effects 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000004968 inflammatory condition Effects 0.000 title claims abstract description 13
- 238000001514 detection method Methods 0.000 title claims description 8
- 239000000090 biomarker Substances 0.000 title description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 30
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 28
- 102000055207 HMGB1 Human genes 0.000 claims abstract description 22
- 108700010013 HMGB1 Proteins 0.000 claims abstract description 22
- 238000001262 western blot Methods 0.000 claims abstract description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 11
- 230000001684 chronic effect Effects 0.000 claims abstract description 6
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims abstract 5
- 238000012286 ELISA Assay Methods 0.000 claims abstract 5
- 101150021904 HMGB1 gene Proteins 0.000 claims abstract 5
- 101001025337 Homo sapiens High mobility group protein B1 Proteins 0.000 claims description 49
- 239000003550 marker Substances 0.000 claims description 12
- 206010009887 colitis Diseases 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 7
- 102000053637 human HMGB1 Human genes 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 238000009010 Bradford assay Methods 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000011536 extraction buffer Substances 0.000 claims description 3
- 230000004927 fusion Effects 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract description 25
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract description 25
- 210000003608 fece Anatomy 0.000 abstract description 14
- 238000004458 analytical method Methods 0.000 abstract description 8
- 230000008506 pathogenesis Effects 0.000 abstract description 4
- 102100037907 High mobility group protein B1 Human genes 0.000 description 43
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 201000010099 disease Diseases 0.000 description 37
- 230000004054 inflammatory process Effects 0.000 description 17
- 206010061218 Inflammation Diseases 0.000 description 16
- 238000007737 ion beam deposition Methods 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 239000000523 sample Substances 0.000 description 10
- 230000009266 disease activity Effects 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 4
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000219061 Rheum Species 0.000 description 3
- 108091006629 SLC13A2 Proteins 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 230000008993 bowel inflammation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010217 densitometric analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 210000001842 enterocyte Anatomy 0.000 description 2
- 229940117360 ethyl pyruvate Drugs 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 210000005027 intestinal barrier Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000003384 transverse colon Anatomy 0.000 description 2
- SXXFNENRGADUMK-ILYOTBPNSA-N (6z,9z,12z)-15-iodo-16-pentyl-1-oxacyclohexadeca-6,9,12-trien-2-one Chemical compound CCCCCC1OC(=O)CCC\C=C/C\C=C/C\C=C/CC1I SXXFNENRGADUMK-ILYOTBPNSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 description 1
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM2010A000442A IT1406051B1 (it) | 2010-08-05 | 2010-08-05 | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
| ITRM2010A000442 | 2010-08-05 | ||
| PCT/IT2011/000276 WO2012017466A1 (en) | 2010-08-05 | 2011-08-01 | Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2807107A1 CA2807107A1 (en) | 2012-02-09 |
| CA2807107C true CA2807107C (en) | 2017-01-03 |
Family
ID=43739596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2807107A Expired - Fee Related CA2807107C (en) | 2010-08-05 | 2011-08-01 | Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20130137123A1 (enExample) |
| EP (1) | EP2601525A1 (enExample) |
| JP (1) | JP2013534313A (enExample) |
| CN (1) | CN103069276A (enExample) |
| AU (1) | AU2011287193B2 (enExample) |
| BR (1) | BR112013002145A2 (enExample) |
| CA (1) | CA2807107C (enExample) |
| CL (1) | CL2013000223A1 (enExample) |
| EA (1) | EA201390197A1 (enExample) |
| IL (1) | IL223845A (enExample) |
| IT (1) | IT1406051B1 (enExample) |
| MX (1) | MX2013001327A (enExample) |
| PE (1) | PE20131062A1 (enExample) |
| WO (1) | WO2012017466A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968443B1 (en) | 2013-03-15 | 2021-09-29 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| EP3094973B1 (en) | 2013-11-07 | 2020-07-29 | Diagnodus Limited | Biomarkers |
| EP3143037B1 (en) | 2014-05-16 | 2021-06-23 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
| CN113563423A (zh) | 2014-07-17 | 2021-10-29 | 领导医疗有限公司 | 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途 |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| US20200064357A1 (en) * | 2016-11-09 | 2020-02-27 | Protagonist Therapeutics, Inc. | Methods for determining and monitoring gastrointestinal inflammation |
| BR112019023772A2 (pt) | 2017-05-12 | 2020-06-09 | Evonik Operations Gmbh | método para detectar doenças induzidas por c. perfringens em animais e kit de diagnóstico |
| IT201700083044A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| IT201700083055A1 (it) | 2017-07-20 | 2019-01-20 | Laura Stronati | “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali” |
| EP4501952A3 (en) | 2018-02-08 | 2025-04-16 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| US12031991B2 (en) | 2018-03-02 | 2024-07-09 | Evonik Operations Gmbh | In vitro method for detecting intestinal barrier failure in animals |
| CN109030817A (zh) * | 2018-07-04 | 2018-12-18 | 长沙都正医学检验有限责任公司 | Hmgb1检测试剂盒及其制备方法 |
| EP3894863B1 (en) | 2018-12-14 | 2022-11-23 | Evonik Operations GmbH | In vitro method for detecting avian intestinal dysbiosis |
| US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
| BR112022014011A2 (pt) | 2020-01-15 | 2022-12-20 | Janssen Biotech Inc | Inibidores peptídicos de receptor de interleucina-23 e seu uso no tratamento de doenças inflamatórias |
| MX2022008741A (es) | 2020-01-15 | 2022-10-03 | Janssen Biotech Inc | Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| WO2022109328A1 (en) | 2020-11-20 | 2022-05-27 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| EP4370146A4 (en) | 2021-07-14 | 2025-05-21 | Janssen Biotech, Inc. | Lipidated peptide inhibitors of the interleukin-23 receptor |
| CN116973572B (zh) * | 2023-06-02 | 2025-03-07 | 东南大学附属中大医院 | 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0964250B1 (en) * | 1996-07-17 | 2007-06-27 | Kaneka Corporation | Diagnostic drugs for autoimmune diseases |
| US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
| US6303321B1 (en) * | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
| US7700307B2 (en) * | 2003-03-08 | 2010-04-20 | Auvation Limited | Mitochondrial stress-70 protein markers for colorectal cancer |
| AU2005333602B2 (en) * | 2004-10-22 | 2012-04-12 | Medimmune, Llc | High affinity antibodies against HMGB1 and methods of use thereof |
| WO2008075788A1 (ja) * | 2006-12-20 | 2008-06-26 | Shino-Test Corporation | ヒトｈｍｇｂ１と特異的に結合する鳥類由来の抗体、ヒトｈｍｇｂ１の免疫学的測定方法及びヒトｈｍｇｂ１の免疫学的測定試薬 |
| EA201000131A1 (ru) * | 2007-08-02 | 2010-08-30 | АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ | Диагностика, определение стадии и мониторинг воспалительного заболевания кишечника |
| WO2009114756A2 (en) * | 2008-03-14 | 2009-09-17 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
-
2010
- 2010-08-05 IT ITRM2010A000442A patent/IT1406051B1/it active
-
2011
- 2011-08-01 CN CN2011800327624A patent/CN103069276A/zh active Pending
- 2011-08-01 MX MX2013001327A patent/MX2013001327A/es unknown
- 2011-08-01 WO PCT/IT2011/000276 patent/WO2012017466A1/en not_active Ceased
- 2011-08-01 PE PE2013000131A patent/PE20131062A1/es not_active Application Discontinuation
- 2011-08-01 BR BR112013002145A patent/BR112013002145A2/pt not_active IP Right Cessation
- 2011-08-01 JP JP2013522346A patent/JP2013534313A/ja active Pending
- 2011-08-01 US US13/814,294 patent/US20130137123A1/en not_active Abandoned
- 2011-08-01 EA EA201390197A patent/EA201390197A1/ru unknown
- 2011-08-01 CA CA2807107A patent/CA2807107C/en not_active Expired - Fee Related
- 2011-08-01 EP EP11754539.2A patent/EP2601525A1/en not_active Withdrawn
- 2011-08-01 AU AU2011287193A patent/AU2011287193B2/en not_active Ceased
-
2012
- 2012-12-24 IL IL223845A patent/IL223845A/en active IP Right Grant
-
2013
- 2013-01-23 CL CL2013000223A patent/CL2013000223A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011287193A1 (en) | 2013-06-13 |
| CA2807107A1 (en) | 2012-02-09 |
| US20130137123A1 (en) | 2013-05-30 |
| CN103069276A (zh) | 2013-04-24 |
| WO2012017466A8 (en) | 2013-07-11 |
| JP2013534313A (ja) | 2013-09-02 |
| AU2011287193B2 (en) | 2015-08-13 |
| WO2012017466A1 (en) | 2012-02-09 |
| IT1406051B1 (it) | 2014-02-06 |
| CL2013000223A1 (es) | 2014-03-28 |
| EP2601525A1 (en) | 2013-06-12 |
| PE20131062A1 (es) | 2013-10-16 |
| EA201390197A1 (ru) | 2013-06-28 |
| ITRM20100442A1 (it) | 2012-02-06 |
| IL223845A (en) | 2016-06-30 |
| BR112013002145A2 (pt) | 2016-05-24 |
| MX2013001327A (es) | 2013-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2807107C (en) | Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof | |
| Zollner et al. | Faecal biomarkers in inflammatory bowel diseases: calprotectin versus lipocalin-2—a comparative study | |
| Leach et al. | Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease | |
| Gisbert et al. | Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease | |
| Kaiser et al. | Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome | |
| D'angelo et al. | Calprotectin in daily practice: where do we stand in 2017? | |
| Montalto et al. | Role of fecal calprotectin in gastrointestinal disorders | |
| KR20100063052A (ko) | 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법 | |
| Klimczak et al. | The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity | |
| Stascheit et al. | Calprotectin as potential novel biomarker in myasthenia gravis | |
| Al | Biochemical significance of cystatin-C and high-sensitive CRP in patients with acute coronary syndrome; any clinical correlation with diagnosis and ejection fraction | |
| Vaiopoulou et al. | Current advantages in the application of proteomics in inflammatory bowel disease | |
| CA2800371A1 (en) | Methods of renal cancer detection | |
| Hamdy et al. | Matrix metalloproteinase-3 as a marker of subclinical activity in rheumatoid arthritis patients: Relation to ultrasonographic activity | |
| US20230074127A1 (en) | Test and in vitro diagnosis of irritable bowel syndrome | |
| Pham et al. | Subclinical intestinal inflammation in siblings of children with Crohn’s disease | |
| Huong et al. | Role of Calprotectin, IL-6, and CRP in distinguishing between inflammatory bowel disease and diarrhea predominant irritable bowel syndrome | |
| Waluga | Biomarkers of irritable bowel syndrome | |
| CN114270191B (zh) | 炎症性肠病诊断方法、诊断探针和诊断试剂盒 | |
| KR20130136964A (ko) | 창자 감염성 병태의 생물학적 마커로서 hmgb1의 용도, 대변 샘플에서 그의 검출을 위한 비침습적 방법 및 키트 | |
| Toğrol et al. | The significance of coeliac disease antibodies in patients with ankylosing spondylitis: a case-controlled study | |
| Wang et al. | Association of serum anti-carbamylated protein antibodies with disease activity and bone loss in rheumatoid arthritis | |
| EP3963334A1 (en) | A method of determining the probability of inflammatory bowel disease in a subject being ulcerative colitis or crohn's disease | |
| TWI614501B (zh) | ５-甲氧基色胺酸作為發炎疾病診斷試劑之用途 | |
| Şimşek et al. | Fecal S100A12 as a Biomarker in Behcet’s Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20160727 |
|
| MKLA | Lapsed |
Effective date: 20220301 |
|
| MKLA | Lapsed |
Effective date: 20200831 |